Objective To examine the epidemiological and economic impact of a nine-valent (nonavalent) human papillomavirus (HPV) 6/11/16/18/ 31/33/45/52/58 vaccine programme for young teenagers in Singapore.
Introduction
Globally, cervical cancer is the fourth most common cancer in female with 538 000 new cases and more than 266 000 deaths in 2012. 1 In Singapore, cervical cancer is the 8th commonest cancer with a crude and aged-standardised incidence rate of 10.8 and 7.2 per 100 000 per year, respectively, between 2006 and 2010. 2 Cervical cancer mortality ranked 8th among female cancer deaths (4.1/100 000 population) for all ages. However, among young women 15-44 years old, the mortality rate had risen from 5th position (0.9/100 000 population) in 2008 to 3rd position (1.0/ 100 000 population) in 2012. 3, 4 The lackluster achievement of cervical cancer control in Singapore may be attributed to several factors: low participation rate (<50%) of cervical screening; low HPV vaccination rate in the hitherto prescription-based voluntary vaccination scheme (estimated to be 7.9% between 2012 and 2014 in a Ministry of Health statement 5 ); and the relative preponderance of HPV subtypes 52, 58, 33 and 31 in cervical samples obtained from women who have no disease as well as those who have CIN2/3 and cervical cancer locally. [6] [7] [8] In Singapore, bivalent (HPV 16/18) and quadrivalent (6/11/16/18) prophylactic HPV vaccines have been available since 2007 and nonavalent HPV vaccine was introduced in April 2017. The newly available nonavalent HPV vaccine has been shown to carry an efficacy of 96.7% against infection by nine HPV subtypes: HPV 6, 11, 16, 18, 31, 33 , 45, 52 and 58. 9 Clinical and economic benefits of nonavalent HPV vaccines over quadrivalent vaccine have been addressed in the USA and Europe but not in other continents. [10] [11] [12] The information deficiency gap needs to be filled, as variation between continents in the contribution of subtypes 52 and 58 to high-grade cervical neoplasia and cancer is evident. 8 More significantly, if the policy-maker is contemplating a school-based universal HPV vaccination programme to improve HPV vaccine uptake rate in Singapore in order to address the pressing need to improve cervical cancer control, it is important to evaluate the additional benefits of nonavalent HPV vaccine compared with bivalent and quadrivalent HPV vaccines in Singapore. The current study was therefore conducted to assess specifically the impact of a school-based nonavalent HPV vaccination for female adolescents, in comparison with bivalent and quadrivalent HPV vaccines, on the clinical burden and cost-effectiveness of control of HPV-related diseases in the female lower genital tract in Singapore.
Methodology
We adapted a previously validated dynamic transmission mathematical model [10] [11] [12] [13] to simulate the impact of schoolbased nonavalent HPV vaccination. Table 1 showed the Singapore epidemiological as well as economic inputs to the model. These included: age-gender specific population distribution, 14 HPV genotype distribution on cervical cancer patients, 8 age-standardised cervical cancer incidence rate and mortality rate. 15 The age and stage-specific cervical cancer mortality and sexual behaviour parameters were derived from published data from Taiwan. 16 The incidence rate of genital warts estimated was based on two studies from Singapore and Taiwan. 17, 18 The characteristics of natural history and neoplastic transition rate of HPV were adopted from internationally published data as used in the original model.
Data input for cytology screening was assumed to remain constant at 50%. 19, 20 The stage-specific (CIN1/CIN2/CIN3) Table S1 ). The treatment cost of genital warts was estimated based on a database of the National Skin Center, Singapore. 17 All costs were in Singapore dollars (SGD) based on the healthcare resource utilisation within the 4 years, and were inflated to 2014 values using the consumer price index in healthcare.
The estimates for quality-adjusted life years (QALYs) were based on the internationally published data used in the previous analyses. 16 The planning time horizon for vaccination in the analysis was 100 years, chosen on the basis that the incidence of cervical-related diseases simulated in this model approached a steady state only after 80 years from the date of vaccination; in addition, the guideline from the International Society of Pharmacoeconomic and Outcomes Research (ISPOR) has recommended that the time period for estimating clinical and cost effectiveness should be sufficiently long to reflect all important differences in costs and health effects between the technologies being compared. 21 The total costs and health effects were estimated based on the population size of Singapore residents in 2014.
14 A discounted value at an annual rate of 3.0% of present-day cost was used in this simulation computation.
The vaccine efficacy input was based on published clinical trial results that nonavalent HPV vaccine reduced HPV 31/33/45/52/58 related high-grade diseases by 96.7%, and HPV 31/33/45/52/58 related cervical epithelial neoplasia and cervical cancer by 96.3%. 9 The efficacy of bivalent and quadrivalent vaccines was based on clinical trials (Table 1) . It was assumed that the HPV vaccination would not change the natural course of HPV infection or disease prevalence at the time of vaccination. Also, we assumed that the duration of protection of HPV vaccination would be lifelong. 22, 23 The outcome measures of the study were: (1) additional reduction in the prevalence of vaccine-related HPV-type infection and burden of their related genital warts, CIN and cervical cancer and (2) incremental cost-effectiveness ratio (ICER) of vaccination with nonavalent HPV vaccination in a school-based programme involving adolescent girls between 11 and 12 years old, compared with similar strategies with quadrivalent or bivalent HPV vaccination. It was assumed that the vaccine coverage was 80% for all the strategies, based on long-term experience of more than 90% uptake rate of childhood immunisation in Singapore.
We programmed all model equations and inputs in MATHEMATICA â (Wolfram Research, Champaign, IL, USA) and used the NDSolve subroutine in MATHEMA-TICA version 5.2 to generate numerical solutions for the differential equations making up the model.
Results
We first compared the impact on reduction of disease burden of a school-based nonavalent HPV vaccination for 80% of 11-to 12-year-old girls over standard cytology screening alone with a participation rate of 80% of eligible women. The results in Table 2 showed a 53.3% reduction in cervical cancer cases and 48.3% reduction in cervical cancer deaths when the vaccination programme was compared with cytology screening alone. The incremental cost effectiveness ratio was SGD 4766. Furthermore, comparison of the impact of nonavalent to the other HPV vaccines from this model simulation showed a significant economic benefit and clinical outcome in nonavalent HPV vaccination compared with quadrivalent and bivalent HPV vaccines over a period of 100 years since the vaccination program started (Figures 1 and 2 ). The impacts are summarised below.
Clinical outcome
Compared with school-based quadrivalent HPV vaccination, the nonavalent HPV vaccination in 80% of 11-to 12-year-old female adolescents resulted in additional reduction in HPV 6/11/16/18/31/33/45/52/58 related cervical cancer of 1786 cases (23.5%) and reduction in cervical cancer mortality of 583 cases (20.2%) ( Table 2) ; there was also a reduction in CIN1 of 15 119 cases (40.5%) and CIN2/3 of 30 506 cases (35.4%).
The same reduction in HPV 6/11/16/18/31/33/45/52/58 related new cases of cervical cancer and cancer deaths was noted in nonavalent HPV vaccination when compared with bivalent vaccination. Moreover, the comparison showed that nonavalent vaccination prevented HPV 6/11-related CIN1 in 7467 cases (75.7%) and genital warts in 137 594 (78.9%) in women and 127 554 cases (73.4%) in men ( Table 2) .
Economic outcome
Nonavalent HPV vaccination was projected to reduce overall treatment cost of HPV 6/11/16/18/31/33/45/52/58 related diseases by SGD 10.49 million (7.5%) when compared with quadrivalent vaccine and, more significantly, by SGD 61.8 million (32.4%) when compared with bivalent vaccine. Compared with quadrivalent vaccination, nonavalent vaccination reduced treatment cost by SGD 2.99 million (7.9%) for cervical cancer, by SGD 1.7 million (18.1%) for CIN1 and by SGD 5.8 million (12.8%) for CIN2/3. When a similar comparison of treatment cost was made between nonavalent and bivalent vaccination, 83.1% of the saving in nonavalent vaccination was derived from prevention of diseases related to HPV 6/11, and the rest (16.9%) diseases due to HPV 31/33/45/52/58. The breakdown of cost-saving in HPV 6/11-related disease included SGD 732 000 (48.6%) for CIN1, SGD 26.7 million (55.3%) for female genital warts and SGD 23.9 million (49.6%) for male genital warts.
Comparison of total vaccine acquisition cost showed that nonavalent HPV vaccination would incur an increment of SGD 70.5 million over quadrivalent HPV vaccine and bivalent vaccine (the acquisition cost of quadrivalent HPV vaccine and bivalent HPV vaccine was assumed to be the same). However, the nonavalent vaccination programme will be able to save SGD 10.4 million in disease management costs over quadrivalent vaccination, and SGD 61.8 million over bivalent vaccination. Therefore, the net cost of nonavalent HPV vaccination was SGD 60 million over and above that of quadrivalent vaccination and SGD 8.7 million over and above that of bivalent vaccination.
Incremental cost-effectiveness ratio (ICER)
In the analysis of the incremental cost needed to gain one additional quality-adjusted life-year (QALY) in an individual perspective, nonavalent HPV vaccination resulted in an additional cost of SGD 15.5 and a gain of 0.00157 QALY per person over quadrivalent vaccination. Thus, the calculated ICER of school-based nonavalent HPV vaccination for 11-year-old girls was SGD 9864 per QALY over and above quadrivalent vaccination. Similar analysis showed that the incremental cost of nonavalent vaccination over bivalent vaccination was SGD 2.25, a gain of 0.00242 QALY per person. The computed ICER was SGD 929 per QALY.
Sensitivity analysis
Data presented in Table 3 showed that the implication from base case remained valid with variation of vaccine The sensitivity analysis was performed to evaluate the impact of variation of vaccine cost for four scenarios: 1 a 10% rise in nonavalent vaccine cost while quadrivalent vaccine cost remained unchanged, 2 a 10% rise in the cost of nonavalent vaccine while bivalent vaccine cost remained unchanged, 3 nonavalent vaccine cost remained unchanged while quadrivalent vaccine cost rose by 10%, 4 nonavalent vaccine cost remained unchanged while bivalent vaccine cost rose by 10%. In scenario (1), the acquisition cost of nonavalent vaccine was SGD 91.6 million higher than that of the quadrivalent vaccine, so the net cost difference (including treatment cost) was SGD 81.2 million. In scenario (2), the acquisition cost of nonavalent vaccine was SGD 126.9 million higher than the bivalent vaccine, and the net cost difference (including treatment cost) was SGD 65.1 million. In terms of scenario (3) and (4), the acquisition cost of nonavalent vaccine was SGD 56.3 million higher than the quadrivalent vaccine and SGD 95.2 million higher than bivalent vaccine, and the net cost difference (including treatment cost) was SGD 45.9 million and SGD 33.7 million, respectively.
We noted that variation in the cytology screening participation rate among the Singapore female population was not related to any discernible reduction in cervical cancer and relevant mortality, CIN2/3 or genital warts from the base case scenario. With a cytology screening rate of 40%, compared with quadrivalent vaccine, the nanovalent vaccine regimen reduced the incidence of HPV 6/11/16/18/31/ 33/45/52/58 related cervical cancer by 23.6%, and cervical cancer mortality by 20.2%. Nonavalent vaccine further resulted in a reduction of CIN1 of 40.2% and CIN2/3 of 34.3%. Compared with bivalent vaccine, nonavalent vaccine reduced genital warts by 78.8% in women and 73.3% in men. However, a rise in the cytology screening HPV, human papilloma virus; QALY, quality-adjusted life years. All estimates were done with costs and QALY discounted at a rate of 3% over 100 years. *Base case assumed duration of vaccine protection for a lifetime, vaccine coverage rate of 80%, vaccine cost of SGD 180 for nonavalent vaccine, SGD 120 for quadrivalent vaccine and SGD 90 for bivalent vaccine, and cytology screening participation rate of 50%.
participation rate to 60% did result in reduction in HPV 6/11/16/18/31/33/45/52/58 related cervical cancer of 23.2%, and in cervical cancer mortality of 20.1%, CIN1 of 40.8% and CIN2/3 of 36.5% in nanovalent vaccine versus quadrivalent vaccine regimen. In this scenario, compared with bivalent vaccine, nonavalent HPV vaccination also reduced genital warts by 78.9 and 73.5% in women and men, respectively. In this sensitivity analysis, the duration of vaccine protection had the most influential impact on ICER and the cytology screening participation rate the least (Table 3) .
Discussion

Main findings
Compared with cytology screening in the best scenario (80% participation rate) alone, a school-based nonavalent HPV vaccination for 80% of 11-to 12-year-old girls would result in a 53.3% reduction in cervical cancer cases and a 48.3% reduction in cervical cancer deaths in Singapore with an incremental cost-effectiveness ratio (ICER) of SGD 4766. When compared with a similar vaccination programme with quadrivalent vaccine, nonavalent HPV vaccine further reduced HPV 6/11/16/18/31/33/45/52/58 related cervical cancer by 1786 cases (23.5%) and cervical cancer mortality by 583 cases (20.2%), CIN1 by 15 119 cases (40.5%) and CIN2/3 by 30 506 cases (35.4%). The ICER was SGD 9864. In a similar scenario with bivalent vaccine, apart from a similar further reduction of cervical cancer incidence and mortality noted above, nonavalent HPV vaccine also prevented HPV 6/11-related CIN1 in 7467 cases (75.7%) and genital warts in 137 594 (78.9%) for women and in 127 554 cases (73.4%) for men. Moving from bivalent to nonavalent HPV vaccine incurred an ICER of SGD 929. Sensitivity analysis of the model simulation indicated that the duration of vaccine protection against HPV infection and vaccination participation rate had a moderate influence on the main outcome measure, whereas a change in the concurrent cytology screening participation had the least measurable impact.
Strengths and limitations
This study is the first report to examine the clinical and economic significance of extended vaccine coverage of HPV infection from four to nine subtypes in Asia. Thus far, this is the only study reporting on the magnitude of benefits of universal nonavalent versus bivalent HPV vaccination. It is noteworthy that nonavalent HPV vaccine is particularly significant as it protects against HPV 52 and HPV 58 infection, which account for one in six high-grade CIN in Singapore. 8 The dynamic mathematical model employed has been well validated. [10] [11] [12] [13] We have further included sensitive analysis of input parameters of clinical importance: duration of vaccine protection, vaccination uptake rate, vaccine cost, and the participation rate of concurrent cytology screening. When the duration of vaccine protection was set alternatively at 20 years, although the ICERs of comparing nonavalent vaccine to quadrivalent and bivalent vaccine are 65 and 165% higher than the base case, the ICERs remained more than 75% below the 1 GDP per capita in Singapore. In terms of vaccine coverage rate, the ICERs with lower vaccine coverage rates still demonstrated that nonavalent HPV vaccine regimen for adolescent female is a cost-effective strategy. Also, although a higher vaccine coverage rate results in higher overall cost, it causes more gain in QALY, from the perspective of impact outcomes and less utilisation of healthcare resource in public health and productivity. Overall, the cost-effectiveness of nonavalent HPV vaccine is robust compared with either quadrivalent or bivalent HPV vaccine, regardless of the alternative settings for both clinical and economic inputs. In this study, cross protection of HPV vaccines to nonvaccine HPV subtypes were ignored for both quadrivalent and bivalent vaccines, as the durability of cross protection is unproven and it is therefore inappropriate to incorporate them into the simulation model spanning over 100 years in this study. 24 Also, estimates of the benefits in this study are conservative, as financial savings on the management costs of obstetric morbidity and improvement on quality of life associated with treatment of high-grade CIN were not taken into account. 25 The study also ignored the extended protection of HPV vaccination on cancer and pre-cancerous conditions of the vagina, vulva and anal canal. 9 
Interpretation
Our results indicated that the most important benefit of nonavalent HPV vaccination over quadrivalent vaccination was the additional reduction in cervical cancer of 1786 cases (23.5%) and reduction in cervical cancer mortality of 583 cases (20.2%) from HPV 31/33/45/52/58 related cancers over a time period of 100 years since vaccination. The large magnitude of the reduction was higher than the estimates reported from USA (13% reduction for cervical cancer and 17% reduction in CIN2/3) or France (18% reduction in cervical cancer and 22% reduction in CIN2/ 3). 10, 11 The better results in our study were attributable to a higher prevalence of HPV 52 and HPV 58 in high-grade CIN and invasive cervical cancer in Singapore compared with European and North American countries. 8 In fact, it is reasonable to speculate that the significant advantage of nonavalent over quadrivalent vaccine seen in Singapore could be extrapolated to the rest of Asian countries because of the common distribution of HPV subtypes in the region. 26 We would like to point out that these clinical benefits of nonavalent HPV vaccine compared with quadrivalent vaccine came with a saving of treatment cost amounting to SGD 10.4 million. In health economic terms, the additional benefit of nonavalent HPV vaccination over quadrivalent HPV vaccination was associated with an incremental cost-effectiveness ratio (ICER) of SGD 9864, a favourable sum, as the gross domestic production per capital in Singapore was SGD 71 318 in 2014. 27 Our study was able to quantify the impact of nonavalent HPV vaccination. There was an additional protection against HPV 6/11-related CIN1 of 7467 cases (75.7%) and genital warts of 137 594 (78.9%) cases in women and 127 554 cases (73.4%) in men. There would be a further reduction of CIN2/3 of 35.4% and cervical cancer of 23.5%. The model simulation estimated that a switch from bivalent to nonavalent HPV vaccination would yield additional cost-savings amounting to a staggering SGD 61.8 million, or a remarkably low ICER of SGD 929 per QALY. The ICER was one-tenth of the ICER when one switched from quadrivalent to nonavalent HPV vaccination. In this respect, previous cost-effectiveness analysis from Singapore has also reported an advantage of quadrivalent vaccine over bivalent vaccine. 28, 29 Evidence from real-world experience of mass HPV vaccination in the previous decade has demonstrated that prophylactic HPV vaccination should form an important part of cervical cancer prevention strategy and a very high vaccine uptake rate of 80-90% can be achieved in school-based HPV vaccination programmes. [30] [31] [32] [33] The long-term impact of mass HPV vaccination is enormous. As yet, there is no school-based HPV vaccination in Singapore despite previous studies showing that school-based HPV vaccination is cost-effective for both quadrivalent and bivalent HPV vaccines. 28, 29, 34 Nonavalent HPV vaccine extends the protection of quadrivalent vaccine to HPV 31/33/45/52/58 infection and related CIN and cervical cancer. It also adds to the bivalent vaccine, the protection of HPV 6/11 infection and related CIN1 and genital warts in women and men. 9, 26 Results of the present study provide a timely evaluation of the additional benefit of the newly available nonavalent HPV vaccine in Singapore.
Conclusion
In conclusion, extended protection of nonavalent HPV vaccine from HPV 31/33/45/52/58 subtypes compared to quadrivalent and HPV-31/33/45/52/58 and HPV-6/11 compared to bivalent vaccine carries a substantial additional clinical and economic benefits in Singapore.
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